Cargando…

Use of Topical Tranexamic Acid to Reduce Blood Loss in Single-Level Transforaminal Lumbar Interbody Fusion

STUDY DESIGN: Nonrandomized, prospective, and case-controlled study. PURPOSE: To evaluate the efficacy and cost-effectiveness of topically applied tranexamic acid (TXA) during different phases of spine surgery. OVERVIEW OF LITERATURE: Perioperative blood loss is the leading cause of postoperative an...

Descripción completa

Detalles Bibliográficos
Autores principales: Mallepally, Abhinandan Reddy, Mahajan, Rajat, Rustagi, Tarush, Goel, Shakti Amar, Das, Kalidutta, Chhabra, Harvinder Singh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Spine Surgery 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595815/
https://www.ncbi.nlm.nih.gov/pubmed/32213797
http://dx.doi.org/10.31616/asj.2019.0134
_version_ 1783601960902983680
author Mallepally, Abhinandan Reddy
Mahajan, Rajat
Rustagi, Tarush
Goel, Shakti Amar
Das, Kalidutta
Chhabra, Harvinder Singh
author_facet Mallepally, Abhinandan Reddy
Mahajan, Rajat
Rustagi, Tarush
Goel, Shakti Amar
Das, Kalidutta
Chhabra, Harvinder Singh
author_sort Mallepally, Abhinandan Reddy
collection PubMed
description STUDY DESIGN: Nonrandomized, prospective, and case-controlled study. PURPOSE: To evaluate the efficacy and cost-effectiveness of topically applied tranexamic acid (TXA) during different phases of spine surgery. OVERVIEW OF LITERATURE: Perioperative blood loss is the leading cause of postoperative anemia associated with prolonged stays in hospital and long recovery times. The direct and indirect costs involved pose a significant economic challenge in developing countries. There is no consensus for topical use of tranexamic acid in spine surgery. METHODS: Patients requiring a single-level TLIF were divided into two groups. In the TXA group (n=75), the wound surface was soaked with TXA (1 g in 100 mL saline solution) for 3 minutes after exposure, after decompression, and before wound closure, and in the control group (n=175) using only saline. Intraoperative blood loss drain volume was recorded on each of the first 2 days immediately after surgery. An estimated cost analysis was made on the basis of the length of hospital stay and the blood transfusion. RESULTS: IBL for the control group was 783.33±332.71 mL and for intervention group 410.57±189.72 mL (p<0.001). The operative time for control group was 3.24±0.38 hours and for intervention group 2.99±0.79 hours (p<0.695). Hemovac drainage on days 1 and 2 for control group was 167.10±53.83 mL and 99.33±37.5 mL, respectively, and for intervention group 107.03±44.37 mL and 53.38±21.99 mL, respectively (p<0.001). The length of stay was significantly shorter in the intervention group (4.8±1.1 days) compared to control group (7.0±2.3 days). The cost of treatment in the intervention group was US dollar (USD) 4,552.57±1,222.6 compared with that in the control group USD 6,529.9±1,505.04. CONCLUSIONS: Topical TXA is a viable, cost-effective method of decreasing perioperative blood loss in major spine surgery with fewer overall complications than other methods. Further studies are required to find the ideal dosage and timing.
format Online
Article
Text
id pubmed-7595815
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Korean Society of Spine Surgery
record_format MEDLINE/PubMed
spelling pubmed-75958152020-11-03 Use of Topical Tranexamic Acid to Reduce Blood Loss in Single-Level Transforaminal Lumbar Interbody Fusion Mallepally, Abhinandan Reddy Mahajan, Rajat Rustagi, Tarush Goel, Shakti Amar Das, Kalidutta Chhabra, Harvinder Singh Asian Spine J Clinical Study STUDY DESIGN: Nonrandomized, prospective, and case-controlled study. PURPOSE: To evaluate the efficacy and cost-effectiveness of topically applied tranexamic acid (TXA) during different phases of spine surgery. OVERVIEW OF LITERATURE: Perioperative blood loss is the leading cause of postoperative anemia associated with prolonged stays in hospital and long recovery times. The direct and indirect costs involved pose a significant economic challenge in developing countries. There is no consensus for topical use of tranexamic acid in spine surgery. METHODS: Patients requiring a single-level TLIF were divided into two groups. In the TXA group (n=75), the wound surface was soaked with TXA (1 g in 100 mL saline solution) for 3 minutes after exposure, after decompression, and before wound closure, and in the control group (n=175) using only saline. Intraoperative blood loss drain volume was recorded on each of the first 2 days immediately after surgery. An estimated cost analysis was made on the basis of the length of hospital stay and the blood transfusion. RESULTS: IBL for the control group was 783.33±332.71 mL and for intervention group 410.57±189.72 mL (p<0.001). The operative time for control group was 3.24±0.38 hours and for intervention group 2.99±0.79 hours (p<0.695). Hemovac drainage on days 1 and 2 for control group was 167.10±53.83 mL and 99.33±37.5 mL, respectively, and for intervention group 107.03±44.37 mL and 53.38±21.99 mL, respectively (p<0.001). The length of stay was significantly shorter in the intervention group (4.8±1.1 days) compared to control group (7.0±2.3 days). The cost of treatment in the intervention group was US dollar (USD) 4,552.57±1,222.6 compared with that in the control group USD 6,529.9±1,505.04. CONCLUSIONS: Topical TXA is a viable, cost-effective method of decreasing perioperative blood loss in major spine surgery with fewer overall complications than other methods. Further studies are required to find the ideal dosage and timing. Korean Society of Spine Surgery 2020-10 2020-03-30 /pmc/articles/PMC7595815/ /pubmed/32213797 http://dx.doi.org/10.31616/asj.2019.0134 Text en Copyright © 2020 by Korean Society of Spine Surgery This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Mallepally, Abhinandan Reddy
Mahajan, Rajat
Rustagi, Tarush
Goel, Shakti Amar
Das, Kalidutta
Chhabra, Harvinder Singh
Use of Topical Tranexamic Acid to Reduce Blood Loss in Single-Level Transforaminal Lumbar Interbody Fusion
title Use of Topical Tranexamic Acid to Reduce Blood Loss in Single-Level Transforaminal Lumbar Interbody Fusion
title_full Use of Topical Tranexamic Acid to Reduce Blood Loss in Single-Level Transforaminal Lumbar Interbody Fusion
title_fullStr Use of Topical Tranexamic Acid to Reduce Blood Loss in Single-Level Transforaminal Lumbar Interbody Fusion
title_full_unstemmed Use of Topical Tranexamic Acid to Reduce Blood Loss in Single-Level Transforaminal Lumbar Interbody Fusion
title_short Use of Topical Tranexamic Acid to Reduce Blood Loss in Single-Level Transforaminal Lumbar Interbody Fusion
title_sort use of topical tranexamic acid to reduce blood loss in single-level transforaminal lumbar interbody fusion
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595815/
https://www.ncbi.nlm.nih.gov/pubmed/32213797
http://dx.doi.org/10.31616/asj.2019.0134
work_keys_str_mv AT mallepallyabhinandanreddy useoftopicaltranexamicacidtoreducebloodlossinsingleleveltransforaminallumbarinterbodyfusion
AT mahajanrajat useoftopicaltranexamicacidtoreducebloodlossinsingleleveltransforaminallumbarinterbodyfusion
AT rustagitarush useoftopicaltranexamicacidtoreducebloodlossinsingleleveltransforaminallumbarinterbodyfusion
AT goelshaktiamar useoftopicaltranexamicacidtoreducebloodlossinsingleleveltransforaminallumbarinterbodyfusion
AT daskalidutta useoftopicaltranexamicacidtoreducebloodlossinsingleleveltransforaminallumbarinterbodyfusion
AT chhabraharvindersingh useoftopicaltranexamicacidtoreducebloodlossinsingleleveltransforaminallumbarinterbodyfusion